Innoviva (INVA) Amortization - Intangibles (2014 - 2026)
Innoviva's (INVA) quarterly Amortization - Intangibles came in at $6.6 million in Q1 2026, up 1.22% YoY from $6.5 million in Q1 2025, and down 66.56% on a QoQ basis from $19.6 million in Q3 2025.
Analysis
Innoviva (INVA) Amortization - Intangibles (2014 - 2026) Analysis & Trends
Innoviva (INVA) has 6 years of Amortization - Intangibles data on file, last reported at $6.6 million in Q1 2026.
- Quarterly Amortization - Intangibles rose 1.22% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.1 million (up 1.09% YoY) and the FY2025 annual result came in at $26.3 million, up 1.45% from the prior year.
- Amortization - Intangibles eased to $6.6 million in Q1 2026, from $19.6 million in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $19.6 million in Q3 2025 to a low of $1.5 million in Q3 2022.
- A 5-year average of $8.8 million and a median of $6.5 million in 2025 frame the typical range for Amortization - Intangibles.
- Annual changes were most pronounced in 2023 — Amortization - Intangibles jumped 912.57% — and 2025, when it advanced 0.54%.
- Tracing INVA's Amortization - Intangibles over 5 years: stood at $1.5 million in 2022, then jumped by 912.57% to $15.3 million in 2023, then increased by 26.74% to $19.4 million in 2024, then advanced by 1.08% to $19.6 million in 2025, then slumped by 66.56% to $6.6 million in 2026.
- The last three Amortization - Intangibles figures came in at $6.6 million (Q1 2026), $19.6 million (Q3 2025), and $6.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.63 Mn |
| Mar 31, 2026 | 6.60 Mn |
| Sep 30, 2025 | 19.64 Mn |
| Jun 30, 2025 | 6.55 Mn |
| Mar 31, 2025 | 6.50 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Jun 30, 2024 | 6.44 Mn |
| Mar 31, 2024 | 6.44 Mn |
| Sep 30, 2023 | 15.30 Mn |
| Jun 30, 2023 | 4.96 Mn |
| Mar 31, 2023 | 3.81 Mn |
| Sep 30, 2022 | 1.51 Mn |
| Sep 30, 2014 | 3.23 Mn |